glp-1 food trends news How brands can win in the era GLP-1 drugs are rewriting America's

Boland BB, Laker RC, OBrien S et al (2022) Peptide-YY(336)/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic beta-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

Your baseline metabolic rate, insulin resistance severity, genetic factors, and hormonal profile all affect treatment response

doi: 10.1136/bmjdrc-2021-002363 57 LvSWangJXuY

Both the YE and R5 LSC subtypes reduced liver injury markers and improved immune balance, with the less mature YE cells exhibiting the greatest efficacy ( Table 2 )

& Liu, X